Target Name: NPIPB3
NCBI ID: G23117
Review Report on NPIPB3 Target / Biomarker Content of Review Report on NPIPB3 Target / Biomarker
NPIPB3
Other Name(s): NPIPB5 | NPIP | Putative NPIP-like protein KIAA0220-like | Nuclear pore complex interacting protein-like 3 | NPIPB | KIAA0220L | Nuclear pore complex-interacting protein family member B3 | Nuclear pore complex-interacting protein-like 3 | KIAA0220 | KIAA0220-like protein | nuclear pore complex-interacting protein-like 3 | protein pps22-1 | NPIPL3 | PI-3-kinase-related kinase SMG-1 isoform 1 homolog | nuclear pore complex-interacting protein B type | NPIB3_HUMAN | Protein pps22-1 | nuclear pore complex interacting protein family member B3

NPIPB3: A Potential Drug Target

NPIPB3 (N-acetyl-L-glutamyl-L-serine), also known as NPIPB5, is a protein that is expressed in various tissues throughout the body. It is a key player in the intracellular signaling pathway known as the Glutamyl-Cysteinyl-L-Aspartate (GCA) pathway, which is involved in a wide range of cellular processes, including cell signaling, stress response, and inflammation.

The GCA pathway is a complex signaling pathway that is activated by the amino acid L-glutamyl-cysteine (GCA), which is produced by the fusion of the amino acids Asp with a Glu at its carbonyl end. GCA can then react with the amino acid Asp to form GCA-ASP, which can then activate various cellular signaling pathways.

NPIPB3 is a key regulator of the GCA pathway. It is a protein that can interact with GCA and prevent it from activating the signaling pathway. This interaction between GCA and NPIPB3 plays a crucial role in maintaining the balance of the pathway and ensuring that it is not activated when it is not needed.

In addition to its role in the GCA pathway, NPIPB3 is also a potential drug target. Its unique structure and the fact that it is expressed in various tissues make it an attractive target for researchers to study.

One of the reasons why NPIPB3 is a promising drug target is its location in the body. It is expressed in various tissues throughout the body, including the brain, heart, and kidneys. This makes it an attractive target for drugs that can target it specifically in these tissues.

Another reason why NPIPB3 is a promising drug target is its role in various diseases. Its involvement in the GCA pathway has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

For example, studies have suggested that NPIPB3 may be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This is because the GCA pathway is involved in the production of the beta-amyloid protein, which is a hallmark of these diseases. Studies have also suggested that NPIPB3 may be involved in the development and progression of cancer, as it has been shown to be involved in the regulation of cell growth and apoptosis.

In addition to its involvement in these diseases, NPIPB3 may also be a potential drug target for other purposes. For example, it has been shown to be involved in the regulation of pain perception, and may be a useful target for pain medications. It has also been shown to be involved in the regulation of inflammation, and may be a useful target for anti-inflammatory drugs.

In conclusion, NPIPB3 is a protein that is expressed in various tissues throughout the body and plays a key role in the intracellular signaling pathway known as the GCA pathway. Its unique structure and its involvement in the regulation of various cellular processes make it an attractive target for drugs. Its potential as a drug target for the treatment of various diseases makes it a promising target for future research.

Protein Name: Nuclear Pore Complex Interacting Protein Family Member B3

The "NPIPB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPIPB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NPIPB4 | NPIPB5 | NPIPB7 | NPIPB8 | NPIPB9 | NPIPP1 | NPL | NPLOC4 | NPM1 | NPM1P13 | NPM1P21 | NPM1P22 | NPM1P25 | NPM1P27 | NPM1P28 | NPM1P35 | NPM1P42 | NPM1P47 | NPM1P48 | NPM2 | NPM3 | NPNT | NPPA | NPPA-AS1 | NPPB | NPPC | NPR1 | NPR2 | NPR3 | NPRL2 | NPRL3 | NPS | NPSR1 | NPSR1-AS1 | NPTN | NPTN-IT1 | NPTX1 | NPTX2 | NPTXR | NPVF | NPW | NPY | NPY1R | NPY2R | NPY4R | NPY4R2 | NPY5R | NPY6R | NQO1 | NQO2 | NR0B1 | NR0B2 | NR1D1 | NR1D2 | NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3